Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13804326 | 0.89 | KMT2A (0.54) | KMT2ATSHRRAB9ANPC1PIK3CD | |
| SCHEMBL855306 | 0.84 | TSHR (0.50) | KMT2ATSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4575280 | 0.84 | TSHR (0.65) | KMT2ATSHRRAB9ANPC1PIK3CD | |
| SCHEMBL24774945 | 0.83 | KMT2A (0.47) | KMT2ATSHRRAB9ANPC1PIK3CD | |
| SCHEMBL17688541 | 0.83 | KMT2A (0.45) | KMT2ATSHRRAB9ANPC1PIK3CD | |
| SCHEMBL403516 | 0.82 | TSHR (0.49) | KMT2ATSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7439969 | 0.82 | TSHR (0.49) | KMT2ATSHRRAB9ANPC1MEN1 | |
| SCHEMBL20329217 | 0.82 | KMT2A (0.47) | KMT2ATSHRRAB9APIK3CDL3MBTL1 | |
| SCHEMBL800617 | 0.81 | PIK3CD (0.50) | KMT2ATSHRRAB9ANPC1PIK3CD | |
| SCHEMBL17057313 | 0.81 | KMT2A (0.59) | KMT2ATSHRRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541124-B2 | Biologically active compound conjugated to a stapled or stitched peptide | SUTURA THERAPEUTICS LTD (TC) | 2023-01-03 | — | — | US | disclosed |
| US-8796460-B2 | Compounds for inhibiting KSP kinesin activity | Mercky Sharp & Dohme Corp. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120070370-A1 | SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-03-22 | — | — | US | disclosed |
| US-20110171172-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME CORP. | 2011-07-14 | — | — | US | disclosed |
| US-20110150757-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME CORP. | 2011-06-23 | — | — | US | disclosed |
| US-20110123435-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME LLC | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541124-B2 | Biologically active compound conjugated to a stapled or stitched peptide | BPGM, TMPO, SLC7A1 | KMT2A 4188/4885TSHR 3970/4885RAB9A 2796/4885 |
| US-20110150757-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | KIF18B, KIF5B, KIF18A | KMT2A 1173/4885TSHR 4290/4885RAB9A 212/4885 |
| US-20120070370-A1 | SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS | KIF2C, SKP1, KIF5B | KMT2A 1820/4885TSHR 3406/4885RAB9A 851/4885 |
| US-20110123435-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | KIF5B, KIF2C, KIFC1 | KMT2A 1219/4885TSHR 4460/4885RAB9A 693/4885 |
| US-20110171172-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | KIF5B, KIF2C, KIFC1 | KMT2A 1007/4885TSHR 4446/4885RAB9A 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.